

Table. 1 Clinical variables of 212 aUC patients treated with EVP.

Clinical Variables	Total cohort (n = 212)	
	n	%
Age (years)		
median (IQR)	75 (69-79)	
< 75	114	53.8
≥ 75	98	46.2
Gender		
male	151	71.2
female	61	28.8
BMI		
median (IQR)	21.7 (19.5-24.0)	
< 22.0	97	45.8
≥ 22.0	115	54.2
ECOG-PS		
0	147	69.3
1	46	21.7
2	15	7.1
3	4	1.9
Primary site of tumor		
upper tract	51	24.1
lower tract	125	59.0
both	36	17.0
Pathology		
pure UC	160	75.5
not pure UC	37	17.4
no data	15	7.1
Location of metastatic sites		
lung	59	27.8
liver	23	10.8
lymph node	133	62.7
CAR (CRP/Alb ratio)		
median (IQR)	2.06 (0.46-8.87)	
CCr (mL/min)		
median (IQR)	46.6 (33.4-60.2)	

aUC: advanced urothelial carcinoma, EVP: enfortumab vedotin and pembrolizumab, BMI: body mass index, ECOG-PS: eastern cooperative oncology group-performance status, CAR: c-reactive protein/albumin ratio, CRP: c-reactive protein, Alb: albumin, CCr: creatinine clearance, IQR: inter quartile range.